【摘要】 目的探讨阿德福韦酯联合安络化纤丸治疗乙肝早中期肝硬化的疗效。方法将120例乙肝早中期肝硬化患者随机分为对照组,阿德福韦酯组及联合组。对照组采用常规护肝对症治疗,阿德福韦酯组在此基础上口服阿德福韦酯,联合组在阿德福韦酯组基础上口服安络化纤丸,均治疗1年。比较三组患者肝功能、门静脉压力和肝纤维化指标变化情况。结果治疗前三组患者肝功能、门静脉压力和肝纤维化指标数据比较差异无统计学意义(P>0.05);治疗后,联合组肝功能、门静脉压力和肝纤维化指标改善情况均明显优于对照组和阿德福韦酯组,组间比较差异显著(P<0.05)。结论阿德福韦酯联合安络化纤丸治疗乙肝早中期肝硬化可改善患者肝功能,降低其门静脉压力指标和肝纤维化指标,值得临床推广应用。更多还原

【Abstract】 Objective To investigate the efficacy of adefovir combined with Anluohuaxian pill in treatment of early and mid hepatitis B cirrhosis(HBV). Methods 120 cases of patients with early and mid HBV were randomly divided into control group, adefovir group and combination group. The control group was treated with conventional and symptomatic treatment for protecting liver; the adefovir group was treated with adefovir dipivoxil on this basis; the combination group was treated with Anluohuaxian pills on the basis of adefovir group. The treatment period was 1 year. The liver function, portal venous pressure and changes of hepatic fibrosis of three groups were compared.Results The liver function, portal pressure and liver fibrosis of three groups before treatment showed no statistically significant difference(P>0.05); after treatment, the improvement of liver function, portal pressure and liver fibrosis of combination group were significantly better than those of control group and adefovir group, with significant difference(P <0.05). Conclusions Adefovir combined with Anluohuaxian pill can improve liver function in treatment of early and mid hepatitis B cirrhosis, reduce the portal pressure and liver fibrosis index, which is worthy of clinical application.更多还原